ReCode Therapeutics
Focus: ReCode Therapeutics is a public biotechnology company focused on nucleic acid therapeutic delivery for rare and metabolic diseases. The company leverages proprietary delivery technologies to advance genetic medicines.
Profile data last refreshed 16h ago · AI intelligence enriched 3w ago
Funding Stage
PUBLIC
Open Jobs
1
Should You Work at ReCode Therapeutics?
AI assessmentReCode offers exposure to cutting-edge delivery science and rare disease genetics with proven technology validation, but limited hiring and early pipeline stage suggest this is best suited for specialists comfortable with long development timelines.
Why Work Here
- Pioneering nucleic acid delivery platform with recent proof-of-activity milestone in Primary Ciliary Dyskinesia (May 2026), validating core technology
Data completeness
4/9 — Basic
Company HealthSolid
Pipeline
Early-stage
6 total
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
Spirometry
Primary Ciliary DyskinesiaClinical Trials (1)
NCT05685186A Longitudinal, Observational Study of Primary Ciliary Dyskinesia in Adults
N/AHelp build intelligence for ReCode Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.